MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40121-021-00574-9

Медицинская библиотека · Infectious diseases and therapy · 2021

Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine.

Boongird Sarinya, Chuengsaman Piyatida, Setthaudom Chavachol, Nongnuch Arkom, Assanatham Montira, Phanprasert Salinnart, Kitpermkiat Rungthiwa, Kiertiburanakul Sasisopin, Malathum Kumthorn, Phuphuakrat Angsana, Davenport Andrew, Bruminhent Jackrapong

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Patients with end-stage kidney disease (ESKD) are at risk of severe coronavirus disease and mortality. Immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inactivated whole-virus vaccine in patients with ESKD has never been explored.

METHODS

We conducted a prospective cohort study of 60 patients with ESKD and 30 healthy controls. All participants received two doses of an inactivated whole-virus SARS-CoV-2 vaccine (Sinovac Biotech Ltd) 4 weeks apart. SARS-CoV-2-specific humoral and cell-mediated immune responses were investigated and referenced with healthy controls.

RESULTS

After two doses, an anti-receptor-binding domain immunoglobulin G of 50 AU/ml or greater was present in 53 of 60 patients (88%) in the ESKD group and all participants (100%) in the control group (P = 0.05). The percentage of patients with ESKD and controls with neutralizing antibodies of 35% threshold or greater was 58% and 88%, respectively (P = 0.01). Furthermore, the proportion of patients with ESKD and S1-specific T cell response was comparable with controls (82% vs. 77%, P = 0.45). Old age, high ferritin level, and low absolute lymphocyte count were independently associated with poor humoral immune responses.

CONCLUSIONS

Patients with ESKD could develop similar SARS-CoV-2-specific cell-mediated immune responses compared to healthy controls, although suboptimal humoral immune responses were observed following two doses of SARS-CoV-2 vaccination. Therefore, patients with ESKD and the abovementioned factors are at risk of generating inadequate humoral immune responses, and a vaccine strategy to elicit greater immunogenicity among these relatively immunocompromised patients is warranted. (Thai Clinical Trials Registry, TCTR20210226002).

Для цитирования: Boongird Sarinya, Chuengsaman Piyatida, Setthaudom Chavachol, Nongnuch Arkom, Assanatham Montira, Phanprasert Salinnart, Kitpermkiat Rungthiwa, Kiertiburanakul Sasisopin, Malathum Kumthorn, Phuphuakrat Angsana, Davenport Andrew, Bruminhent Jackrapong. Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine.. Infectious diseases and therapy. 2021. DOI: 10.1007/s40121-021-00574-9.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.